Anastrozole

CLINICAL USE


Treatment of breast cancer in post-
menopausal women

DOSE IN NORMAL RENAL FUNCTION


1 mg daily

PHARMACOKINETICS


  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    293.4
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    40
  • %Excreted unchanged in urine &nbsp &nbsp :
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp :
  • Volume of distribution (L/kg) &nbsp &nbsp &nbsp :
    No data
  • half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :
    40–50/Probably
    unchanged

    DOSE IN RENAL IMPAIRMENT


    GFR (mL/MIN)


  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES


  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:
    Dialysed. Dose as in normal renal
    function

  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    Dialysed. Dose as in normal renal
    function
  • HDF/high flux &nbsp :
    Dialysed. Dose as in normal renal
    function
  • CAV/VVHD &nbsp &nbsp &nbsp:
    Dialysed. Dose as in normal renal
    function

    IMPORTANT DRUG INTERACTIONS

  • Potentially hazardous interactions with other drugs
  • Oestrogen-containing therapies: avoid

    concomitant administration as would
    negate pharmacological action

  • amoxifen: avoid concomitant

    administration

    ADMINISTRATION


    Reconstition



    Route


    Oral

    Rate of Administration



    Comments



    OTHER INFORMATION

  • Anastrozole is extensively metabolised in

    the liver; only 10% of unchanged drug and
    60% of metabolites (largely inactive) are
    excreted in the urine

  • Although renal clearance of anastrozole

    decreases proportionally with creatinine
    clearance, the reduction in renal clearance
    does not affect total body clearance of
    anastrozole. According to the American
    SPC a dose reduction is not required in
    renal impairment

  • In the UK, the SPC recommends avoiding

    the use of anastrozole in patients with
    GFR<20 mL/min

  • Related News